Adding enzalutamide to ADT cuts risk for metastasis by 58% in prostate cancer subgroup

The addition of enzalutamide to androgen deprivation therapy extended metastasis-free survival among men with nonmetastatic, hormone-sensitive prostate cancer with high-risk biochemical recurrence, according to study results.
The findings of the randomized, phase 3 EMBARK study, presented during American Urological Association Annual Meeting, also showed a statistically significant and clinically meaningful metastasis-free survival (MFS) benefit with enzalutamide (Xtandi; Astellas Pharma, Pfizer) as monotherapy vs. placebo and ADT. The androgen receptor signaling inhibitor also had a safety

The addition of enzalutamide to androgen deprivation therapy extended metastasis-free survival among men with nonmetastatic, hormone-sensitive prostate cancer with high-risk biochemical recurrence, according to study results.
The findings of the randomized, phase 3 EMBARK study, presented during American Urological Association Annual Meeting, also showed a statistically significant and clinically meaningful metastasis-free survival (MFS) benefit with enzalutamide (Xtandi; Astellas Pharma, Pfizer) as monotherapy vs. placebo and ADT. The androgen receptor signaling inhibitor also had a safety